comparative effectiveness

Research in Review

Maintenance Therapy After Autologous Stem Cell Transplant Improves Survival in MCL

04/18/2017

JCP Editors

Younger patients with mantle cell lymphoma (MCL) who receive an autologous hematopoietic cell transplant after an induction regimen are more likely to prolong their survival with maintenance therapy. ----- Related...

...

04/18/2017

Journal of Clinical Pathways

Research in Review

Maintenance Therapy Effective in Treating Diffuse Large B-Cell Lymphoma

04/12/2017

JCP Editors

Maintenance therapy with a targeting agent may provide survival benefits beyond first- and second-line chemotherapy in patients with diffuse large B-cell lymphoma, according to an analysis published in PLOS One...

...

04/12/2017

Journal of Clinical Pathways

Department

Cost-Effectiveness Analysis Reveals Optimal Immunotherapy for Metastatic NSCLC

04/12/2017

JCP Editors

Recent research suggests a particular immunotherapy may be less costly and offer time savings compared with nivolumab for patients with metastatic non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors,...

Recent...

04/12/2017

Journal of Clinical Pathways

Department

Pazopanib More Cost-Effective Than Sunitinib for Patients With Renal Cell Carcinoma

04/12/2017

JCP Editors

Medicare patients with advanced renal cell carcinoma benefit from lower costs and hospital admissions if treated with pazopanib (Votrient, Novartis) rather than sunitinib (Sutent, Pfizer). Advanced renal cell...

...

04/12/2017

Journal of Clinical Pathways

Research in Review

Autologous Stem Cell Transplantation Improves Outcomes for Patients With MCL

04/11/2017

JCP Editors

Patients with mantle cell lymphoma (MCL) benefit from prolonged event-free survival (EFS) and overall survival (OS) when treated with autologous stem cell transplantation (ASCT) and total body irradiation, according...

...

04/11/2017

Journal of Clinical Pathways

Research Reports

Length of Stay and Costs of COPD: Analysis of Hospitalized Patients Treated With Arformoterol or Nebulized Short-Acting Beta2-Agonists

04/11/2017

Krithika Rajagopalan, PhD

Scott B Robinson, PhD

Frank R Ernst, PharmD, MS

Tina Hunter, PhD

Bernadette H Johnson, MBA

Vamsi K Bollu, PhD, MBA

Abstract: Hospitalization costs are substantial in chronic obstructive pulmonary disease (COPD). Little is known regarding the effect of long-acting beta2-agonists (LABAs) vs short-acting beta2-agonists (SABAs) on...

...

04/11/2017

Journal of Clinical Pathways

Research in Review

B-Cell ALL Disease Burden May Influence CAR T-Cell Therapy Impact on Survival

04/10/2017

JCP Editors

CD19-specific chimeric antigen receptor (CAR) T-cell therapy is more likely to be effective when given immediately after front-line therapy rather than after relapse in certain patients with B-cell acute...

...

04/10/2017

Journal of Clinical Pathways

Research in Review

Genomic Analyses Guide Targeted Therapies for Metastatic Cancers

04/07/2017

JCP Editors

High-throughput genomic analyses may improve outcomes in patients with types of metastatic cancer, according to results of a recent trial published in Cancer Discovery (published online April 1, 2017;...

...

04/07/2017

Journal of Clinical Pathways

Research in Review

Pazopanib Cost-Effective for Patients With Renal Cell Carcinoma

03/28/2017

JCP Editors

Medicare patients with advanced renal cell carcinoma benefit from lower costs and hospital admissions if treated with pazopanib rather than sunitinib, according to research presented at the AMCP Managed Care &...

...

03/28/2017

Journal of Clinical Pathways

Research in Review

Shorter Radiotherapy Regimen Effective in Treating Localized Prostate Cancer

03/20/2017

JCP Editors

A 4-week precision radiotherapy regimen is as effective and safe as the standard 8-week regimen for treating localized prostate cancer, according to research published in the Journal of Clinical Oncology (published...

A...

03/20/2017

Journal of Clinical Pathways